Lupin and Zydus Lifesciences have moved on the first US launches of generic versions of Astellas Pharma’s Myrbetriq (mirabegron) extended-release tablets ‘at-risk’, after a US district court recommended against granting injunctive relief to the Japanese originator for its branded treatment for overactive bladder.
The two Indian firms confirmed immediate launch of their 25mg versions of generic mirabegron, while Zydus also indicated that it was “prepared to launch
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?